Arena gets 10/22 PDUFA date for lorcaserin

Arena Pharmaceuticals should know by October 22 if its closely-watched obesity drug--lorcaserin--will win approval by the FDA. The drug is widely viewed as a likely blockbuster if it breaks into the huge market for weight-loss drugs. "With an October PDUFA date for the lorcaserin NDA, we are another step closer to our goal of improving the treatment of obesity. We believe that lorcaserin, if approved, will be well positioned as first-line therapy to help patients achieve sustainable weight loss in a well-tolerated manner," says CEO Jack Lief. A total of 8,576 patients have been enrolled in 18 clinical trials for the therapy. Arena release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.